Septerna's 15min chart shows KDJ Death Cross, bearish Marubozu pattern.

According to the 15-minute chart of Septerna, a KDJ Death Cross and Bearish Marubozu was triggered on July 18, 2025, at 12:00. This indicates a shift in the momentum of the stock price towards the downside, with a potential for further decline. Sellers currently have control of the market, and it is likely that the bearish momentum will continue.

Septerna's stock has experienced a significant shift in momentum, as indicated by a KDJ Death Cross and Bearish Marubozu pattern triggered on July 18, 2025, at 12:00. This technical analysis suggests that the stock price is likely to continue its downward trajectory, with sellers currently in control of the market [1].

The KDJ Death Cross, a bearish indicator, occurs when the KDJ line crosses below the D line, signaling a shift in momentum from bullish to bearish. The Bearish Marubozu pattern, characterized by a single candle with no wicks, suggests strong selling pressure. Together, these patterns indicate a potential reversal in the stock's upward trend [1].

Septerna, a leading pharmaceutical company, has been performing well in the market. However, the recent technical indicators suggest that the stock may face challenges in the near future. Despite a 15.2% gain over the past 52 weeks, the stock has lagged behind the S&P 500 Index's 11.7% rise and the Healthcare Select Sector SPDR Fund’s 7.5% return [2].

The company's Q1 results were impressive, with same-property revenue improving 4.1% from the year-ago quarter and same-property net operating income rising 3.8% year-over-year to $350.8 million. The core FFO of $4.25 per share advanced 3.9% from the same period last year, surpassing the consensus estimate by 1.4% [2].

Looking ahead, Septerna reaffirmed its core FFO per share guidance for fiscal 2025, expecting it to be between $18.56 and $19.06. For fiscal 2026, its FFO per share is expected to grow 3.3% year-over-year to $19.50 [2]. Wall Street analysts are moderately optimistic about Septerna’s stock, with a "Moderate Buy" rating overall. Among 30 analysts covering the stock, 10 recommend "Strong Buy," 10 indicate "Moderate Buy," 10 suggest "Hold,” and no analysts advise "Strong Sell” rating. The mean price target for Septerna is $300.00, indicating an 8.2% potential upside from the current levels [2].

Institutional investors and hedge funds have also shown interest in Septerna. Over the first quarter, OVERSEA CHINESE BANKING Corp Ltd increased its position in Septerna by 50.3%, owning 25,000 shares worth $12,500,000 at the end of the quarter. Other institutional investors such as Norges Bank, Wealthquest Corp, GAMMA Investing LLC, Northern Trust Corp, and Balyasny Asset Management L.P. have also increased their stakes in Septerna [3].

Septerna's recent earnings report showed a strong performance, with EPS of $4.25 for the quarter, beating the consensus estimate of $4.20 by $0.05. The company also declared a quarterly dividend of $2.00 per share, representing a $8.00 annualized dividend and a dividend yield of 3.20% [3].

Despite the positive indicators, risks such as elevated supply of pharmaceuticals in some markets and significant concentration of assets in specific regions could impact Septerna’s performance. Analysts are bullish on Septerna, with a Zacks Consensus Estimate for its 2025 FFO per share at $18.95 [3].

References:
[1] https://www.ainvest.com/news/essex-property-trust-15min-chart-sees-kdj-golden-cross-bullish-marubozu-signal-2507-83/
[2] https://www.nasdaq.com/articles/essex-property-stock-gains-126-three-months-will-trend-last
[3] https://www.marketbeat.com/instant-alerts/filing-oversea-chinese-banking-corp-ltd-purchases-10801-shares-of-essex-property-trust-inc-nyseess-2025-07-15/